

1 **Variation in lung function and alterations in cardiac**
2 **structure and function – analysis of the UK Biobank**
3 **cardiovascular magnetic resonance imaging substudy**

4 Ross J Thomson¹, Nay Aung¹, Mihir M Sanghvi¹, José Miguel Paiva¹, Aaron M Lee¹, Filip
5 Zemrak¹, Kenneth Fung¹, Paul E Pfeffer PhD², Alexander J Mackay², Tricia M McKeever³,
6 Elena Lukaschuk⁴, Valentina Carapella⁴, Young Jin Kim⁴, Charlotte E Bolton³, Stefan K
7 Piechnik⁴, Stefan Neubauer⁴, Steffen E Petersen^{1*}

8

9 ¹William Harvey Research Institute, NIHR Biomedical Research Centre at Barts, Queen Mary
10 University of London, London, UK

11

12 ²Barts Health NHS Trust, London, UK

13

14 ³Nottingham Respiratory Research Unit, NIHR Nottingham Biomedical Research Centre,
15 School of Medicine, City Hospital NUH Trust Campus, University of Nottingham,
16 Nottingham, UK

17

18 ⁴Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
19 Oxford, Oxford, UK

20

21 *Corresponding Author

22 s.e.petersen@qmul.ac.uk (SEP)

23 **Abstract**

24

25 **Background**

26 Reduced lung function is common and associated with increased cardiovascular morbidity

27 and mortality, even in asymptomatic individuals without diagnosed respiratory disease.

28 Previous studies have identified relationships between lung function and cardiovascular

29 structure in individuals with pulmonary disease, but the relationships in those free from

30 diagnosed cardiorespiratory disease have not been fully explored.

31

32 **Methods & Results**

33 UK Biobank is a prospective cohort study of community participants in the United Kingdom.

34 Individuals self-reported demographics and co-morbidities, and a subset underwent

35 cardiovascular magnetic resonance (CMR) imaging and spirometry. CMR images were

36 analysed to derive ventricular volumes and mass. The relationships between CMR-derived

37 measures and spirometry and age were modelled with multivariable linear regression,

38 taking account of the effects of possible confounders.

39

40 Data were available for 4,975 individuals, and after exclusion of those with pre-existing

41 cardiorespiratory disease and unacceptable spirometry, 1,406 were included in the

42 analyses. In fully-adjusted multivariable linear models lower FEV₁ and FVC were associated

43 with smaller left ventricular end-diastolic (−5.21ml per standard deviation (SD) change in

44 FEV₁, −5.69ml per SD change in FVC), end-systolic (−2.34ml, −2.56ml) and stroke volumes

45 (−2.85ml, −3.11ml); right ventricular end-diastolic (−5.62ml, −5.84ml), end-systolic (−2.47ml,

46 -2.46ml) and stroke volumes (-3.13ml, -3.36ml); and with lower left ventricular mass
47 (-2.29g, -2.46g). Changes of comparable magnitude and direction were observed per
48 decade increase in age.

49

50 **Conclusions**

51 This study shows that reduced FEV₁ and FVC are associated with smaller ventricular volumes
52 and reduced ventricular mass. The changes seen per standard deviation change in FEV₁ and
53 FVC are comparable to one decade of ageing.

54 **Introduction**

55

56 Respiratory disease is common and under-diagnosed, and a significant and growing cause of
57 death and disability[1]. Much of the excess morbidity and mortality is secondary to
58 cardiovascular disease[2]. In a prospective cohort study of 7,575 patients with chronic
59 obstructive pulmonary disease (COPD) from Saskatchewan, Canada[3], the quintile of
60 patients with the most severe COPD had relative risks between 1.4 and 3.1 for all-cause
61 mortality, cardiovascular mortality, congestive heart failure, and angina.

62

63 Lung function is independently associated with cardiovascular morbidity and mortality[4,5],
64 both in individuals with established respiratory disease and in those without any diagnosis
65 or symptoms. In a prospective study of 15,000 individuals in the west of Scotland[6], those
66 in the lowest quintile for forced expiratory volume in first second (FEV₁) had an all-cause
67 mortality almost twice that of the highest quintile. The risks were similar in asymptomatic
68 (subclinical) individuals.

69

70 The prevalence of subclinical impaired lung function is great: in the National Health and
71 Nutrition Examination Survey (NHANES) and NHANES III cohort studies of community
72 volunteers in the United States[7] around 12-13% of individuals had an FEV₁ to forced vital
73 capacity (FVC) ratio less than 0.7, the generally accepted cut-off for obstructive lung
74 disease[8]. Almost three quarters of these individuals did not have a diagnosis of lung
75 disease, and most of the undiagnosed individuals reported good or excellent health.

76 Mortality was higher in those with abnormal spirometry, irrespective of the presence of
77 diagnosed lung disease.

78

79 Previous work has explored some of the relationships between lung disease and
80 cardiovascular structure. Using data from the MESA cohort, Grau and colleagues[9]
81 demonstrated that emphysema severity, quantified with thoracic computed tomography, is
82 inversely correlated with right ventricular volumes and mass. They also found that right
83 ventricular mass is inversely associated with the FEV₁ to FVC ratio. Barr *et al.*[10] continued
84 this analysis to identify a similar correlation between emphysema severity and left
85 ventricular volumes and mass, and between the FEV₁ to FVC ratio and left ventricular end-
86 diastolic and stroke volumes. These analyses were conducted in an all-comers population,
87 many of whom had existing cardiovascular and respiratory disease. Furthermore, the effects
88 of FEV₁ and FVC *per se* were not studied. Given the prevalence of subclinical changes in lung
89 function, together with the associations with adverse outcomes, we set out to explore the
90 relationships between lung function and cardiovascular structure and function in a
91 population free from diagnosed cardiovascular and respiratory disease.

92 **Methods**

93

94 UK Biobank is a large prospective cohort study of approximately 500,000 unselected
95 community volunteers aged 40 to 69 at the time of enrolment, living in the United Kingdom.

96 The design and conduct of the study have been described in detail previously[11]. This study

97 was covered by the general ethical approval for UK Biobank studies from the NHS National

98 Research Ethics Service on 17th June 2011 (Ref 11/NW/0382). None of the authors had

99 direct contact with the study participants. This report is a cross-sectional analysis of the

100 subset of participants who took part in the imaging pilot programme.

101

102 Demographics and doctor-diagnosed co-morbidities were self-reported by electronic

103 questionnaire and interview with a healthcare professional. Data collected during the

104 imaging visit were used in the analyses, except where unavailable, in which case data from

105 the enrolment visit were used. If a participant did not answer a question regarding a

106 comorbid diagnosis, or did not know, it was assumed they did not have the condition.

107 Physical measurements (height, weight, blood pressure, heart rate) and smoking status

108 were captured exclusively at the time of imaging.

109

110 Smokers were defined as individuals who smoke, or used to smoke, on all or most days.

111 Those who smoked occasionally were deemed to be never smokers. For current or previous

112 smokers, pack year history was calculated as the product of the number of packs of

113 cigarettes smoked per day and the difference between age started smoking and age

114 stopped smoking (or age at imaging for current smokers).

115

116 **Cardiovascular magnetic resonance**

117

118 A subgroup of participants is undergoing cardiovascular magnetic resonance imaging (CMR).

119 The CMR acquisition protocol and post-processing have been described previously[12]. In

120 brief, participants underwent imaging using a 1.5 Tesla Siemens MAGNETOM Aera scanner

121 (Siemens Healthcare GmbH, Erlangen, Germany) at a central imaging centre. Short and long

122 axis cine images were acquired using a balanced steady state free precession sequence.

123 Manual image analysis was performed across two core imaging centres using cvi42 version

124 5.1.1 (Circle Cardiovascular Imaging, Calgary, Canada) by observers blinded to all clinical

125 information. The software used these contours to calculate right and left ventricular end-

126 diastolic, end-systolic, and stroke volumes; right and left ventricular ejection fraction; and

127 left ventricular mass. The manual image analysis and quality control, including assessment

128 of intra- and inter-observer variability, have been described in detail previously[13].

129

130 **Spirometry**

131

132 Spirometry without bronchodilator administration was performed at the time of imaging

133 according to a standard protocol using a Vitalograph Pneumotrac 6800 spirometer [14].

134 Each participant produced two blows, and a third if there was unacceptable variance in the

135 first two (as calculated by the spirometer). The forced expiratory volume in one second

136 (FEV₁), forced vital capacity (FVC), and an automated assessment of measurement quality

137 were recorded.

138

139 Spirometry blows were excluded from the analysis if the automated quality assessment was
140 anything other than 'acceptable'. Participants were excluded if they had fewer than two
141 acceptable blows, if the coefficient of variation for the two or three acceptable blows
142 exceeded 5%, or if the difference between the best and second best acceptable blow
143 exceeded 150ml, in accordance with established guidelines[8]. To investigate the potential
144 impact of these exclusion criteria on the results we performed a sensitivity analysis in which
145 all participants with at least two 'acceptable' spirometry blows were included, without any
146 limit on the permissible range or coefficient of variation between blows. The results of this
147 sensitivity analysis are presented in Supplementary Information S2. Obstructive spirometry
148 was defined as an FEV₁ to FVC ratio less than 0.7.

149

150 **Statistical analysis**

151

152 The CMR-derived parameters and FEV₁ and FVC were approximately normally distributed
153 and the assumptions for linear regression were satisfied. FEV₁ and FVC were standardised to
154 the mean (FEV₁ mean 2.87 litres, SD 0.70 litres; FVC mean 3.73 litres, SD 0.89 litres).

155

156 The relationships between nine CMR-derived parameters and both FVC and FEV₁ were
157 modelled with multivariable linear regression, using age, sex, ethnicity, height, weight,
158 systolic blood pressure, resting heart rate, Townsend deprivation index (a commonly used
159 measure of material deprivation where positive values represent above-average deprivation
160 and negative values below-average deprivation), education level (categorised as the

161 presence or absence of a degree or professional qualification), regular alcohol consumption
162 (defined as three or more occasions per week), smoking history (pack years) and any
163 diagnosis of hypertension or diabetes as co-variables. Height and weight were included as
164 covariates in the regression models, rather than indexing the dependent variables to body
165 surface area, since the use of ratios in regression analysis is liable to spurious results and
166 misinterpretation[15,16]. The approach adopted ensures all variables in the model are
167 appropriately adjusted for body composition.

168

169 To place the effects of spirometry on CMR-derived parameters in context, the relationships
170 between the CMR-derived parameters and age were modelled in a similar fashion, except
171 that both FEV₁ and FVC were used as co-variables. Interaction terms were used to explore
172 any stratification by sex in the relationships between the CMR-derived parameters and the
173 primary exposure variable (FEV₁, FVC, or age) in each regression model.

174

175 Each regression analysis was performed on a complete-case basis without imputation of
176 missing data. Nine of thirteen covariates had no missing data, and the covariate with most
177 missing data (alcohol consumption) lacked fewer than one percent of observations. The
178 outcome variables (CMR-derived parameters) had fewer than two percent missing
179 observations, which were clustered in 22 participants who were missing all the outcome
180 variables and another one who was missing right ventricular parameters.

181

182 Regression coefficients are presented as the change in the CMR-derived parameter per
183 standard deviation change in FEV₁ or FVC, or per decade change in age. P values were

184 calculated using Student's t test or ANOVA for continuous variables and Chi-squared test for
185 categorical variables. Statistical analyses were performed using *R* version 3.3.2[17].

186 **Results**

187

188 1,221 individuals were excluded on account of pre-existing cardiorespiratory disease, the
189 definition of which is provided in Supplementary Information S1. Of the remaining 3,754
190 individuals, a further 2,348 were excluded in the primary analysis because they did not meet
191 the criteria for reproducible and acceptable spirometry. The case selection process for the
192 primary analysis is shown in Fig 1.

193

194 **Fig 1. Case selection flowchart for the primary analysis**

195

196 1,406 participants were included in the primary analysis. On account of missing data, the
197 number of observations in the regression models was 1,366 or 1,367 depending on the
198 CMR-derived parameter being studied. Baseline characteristics, stratified by tertile of FEV₁,
199 are described in Table 1. Compared to those in the highest tertile, those in the lowest tertile
200 of FEV₁ were older, more likely to be female, shorter, lighter, had lower diastolic blood
201 pressure and higher resting heart rates, and were more likely to have obstructive
202 spirometry.

204 **Table 1. Baseline characteristics of the study population by tertile of FEV₁**

	Tertile of FEV ₁			P value
	1 st (n = 475)	2 nd (n = 468)	3 rd (n = 463)	
Age (years)	57.6 (6.6)	53.8 (7.8)	52.3 (7.5)	< 0.001
Sex (male)	41 (9%)	162 (35%)	396 (86%)	< 0.001
Height (cm)	163 (7)	168 (7)	177 (7)	< 0.001
Weight (kg)	68 (13)	73 (15)	82 (13)	< 0.001
Diastolic BP (mmHg)	78 (10)	78 (10)	80 (9)	0.002
Systolic BP (mmHg)	137 (19)	135 (18)	137 (16)	0.976
Resting heart rate (beats per minute)	72 (10)	69 (11)	68 (12)	< 0.001
Townsend deprivation index	-1.99 (2.76)	-2.01 (2.66)	-1.84 (2.75)	0.388
Hypertension	128 (27%)	130 (28%)	121 (26%)	0.852
Diabetes	22 (5%)	15 (3%)	22 (5%)	0.423
Obstructive spirometry ^a	63 (13%)	34 (7%)	19 (4%)	< 0.001
Smoking history (pack years)	4.71 (10)	4.87 (11)	5.23 (11)	0.448
Educational level (degree or professional qualification)	312 (66%)	304 (65%)	314 (68%)	0.632
Ethnicity (white)	456 (97%)	457 (98%)	455 (98%)	0.428
Alcohol consumption (three or more drinks per week)	88 (19%)	87 (19%)	98 (21%)	0.524

206

207 Data represent mean (standard deviation) or n (percentage) for continuous and categorical
208 variables, respectively.

209 The cut-offs between the first and second and second and third tertiles, of FEV₁ were 2.5
210 litres and 3.09 litres, respectively.

211 P values by ANOVA or Chi-squared test.

212 ^aObstructive spirometry defined as an FEV₁ to FVC ratio < 0.7.

213

214 Following adjustment for potential confounders in a multivariable linear model, lower FEV₁
215 and FVC were associated with smaller left ventricular (LV) end-diastolic volume, LV end-
216 systolic volume, LV stroke volume, right ventricular (RV) end-diastolic volume, RV end-
217 systolic volume, RV stroke volume, and LV mass (Table 2). The interaction terms between
218 the primary exposure variables and sex were not statistically significant and thus there were
219 no differences in the observed relationships between males and females. The linear
220 relationships between CMR-derived parameters and FEV₁ and FVC are shown in the figures
221 in Supplementary Information S3 and S4, respectively.

222 **Table 2. Effects of lung function on CMR-derived parameters**

CMR Parameter	FEV ₁ (standardised)				FVC (standardised)			
	Effect	95% CI		P value	Effect	95% CI		P value
	estimate	Lower	Upper		estimate	Lower	Upper	
Left ventricular end-diastolic volume (ml)	-5.21	-7.42	-3.00	< 0.001	-5.69	-8.03	-3.36	< 0.001
Left ventricular end-systolic volume (ml)	-2.34	-3.78	-0.89	0.002	-2.56	-4.09	-1.03	0.001
Left ventricular stroke volume (ml)	-2.85	-4.22	-1.49	< 0.001	-3.11	-4.55	-1.67	< 0.001
Left ventricular mass (g)	-2.29	-3.77	-0.82	0.002	-2.46	-4.02	-0.89	0.002
Left ventricular ejection fraction (%)	NS	-0.55	0.60	0.927	NS	-0.56	0.65	0.886
Right ventricular end-diastolic volume (ml)	-5.62	-7.98	-3.26	< 0.001	-5.84	-8.34	-3.34	< 0.001
Right ventricular end-systolic volume (ml)	-2.47	-4.03	-0.92	0.002	-2.46	-4.10	-0.82	0.003
Right ventricular stroke volume (ml)	-3.13	-4.50	-1.76	< 0.001	-3.36	-4.81	-1.91	< 0.001
Right ventricular ejection fraction (%)	NS	-0.68	0.48	0.739	NS	-0.78	0.44	0.588

223

224 Effect sizes represent the change of the CMR parameter per standard deviation reduction in FEV₁ or FVC in a multivariable linear regression
225 adjusted for age, sex, ethnicity, height, weight, systolic blood pressure, resting heart rate, Townsend deprivation index, education level, regular
226 alcohol consumption, smoking history, and any diagnosis of hypertension or diabetes. CI; confidence interval. NS; not statistically significant.

227 In a similar multivariable linear model, increasing age was associated with smaller LV end-
 228 diastolic volume (-3.96ml, -6.01ml to -1.92ml), LV end-systolic volume (-1.52ml, -2.86ml
 229 to -0.17ml, LV stroke volume (-2.47ml, -3.73ml to -1.20ml), RV end-diastolic volume
 230 (-5.30ml, -7.49ml to -3.11ml), RV end-systolic volume (-3.03ml, -4.47ml to -1.59ml), and
 231 RV stroke volume (-2.30ml, -3.57ml to -1.03ml) (Table 3). Values represent the mean and
 232 lower and upper 95% confidence intervals for the change in CMR-derived parameter per
 233 decade increase in age. FEV₁, FVC, and age did not influence right or left ventricular ejection
 234 fraction. Age did not influence left ventricular mass. The relative effect sizes of FEV₁, FVC,
 235 and age on CMR-derived parameters are shown in Fig 2.
 236

237 **Table 3. Effects of age on CMR-derived parameters**

CMR Parameter	Age (decades)			
	Effect estimate	95% CI		P value
		Lower	Upper	
Left ventricular end-diastolic volume (ml)	-3.96	-6.01	-1.92	< 0.001
Left ventricular end-systolic volume (ml)	-1.52	-2.86	-0.17	0.027
Left ventricular stroke volume (ml)	-2.47	-3.73	-1.20	< 0.001
Left ventricular mass (g)	NS	-2.58	0.16	0.083
Left ventricular ejection fraction (%)	NS	-0.39	0.67	0.614
Right ventricular end-diastolic volume (ml)	-5.30	-7.49	-3.11	< 0.001
Right ventricular end-systolic volume (ml)	-3.03	-4.47	-1.59	< 0.001

Right ventricular stroke volume (ml)	-2.30	-3.57	-1.03	< 0.001
Right ventricular ejection fraction (%)	NS	-0.13	0.94	0.142

238

239 Effect sizes represent the change of the CMR parameter per decade increase in age in a
 240 multivariable linear regression adjusted for FEV₁, FVC, sex, ethnicity, height, weight, systolic
 241 blood pressure, resting heart rate, Townsend deprivation index, education level, regular
 242 alcohol consumption, smoking history, and any diagnosis of hypertension or diabetes. CI;
 243 confidence interval. NS; not statistically significant

244

245 **Fig 2. Effect sizes for the change in CMR-derived parameter per standard deviation**
 246 **reduction in FEV₁ and FVC, and per one decade increase in age**

247 Filled shapes represent the change in the CMR-derived parameter per standard deviation
 248 reduction in FEV₁ or FVC, or per decade increase in age. Error bars represent the 95%
 249 confidence interval for the effect estimate.

250

251 In a sensitivity analysis employing a broader definition of acceptable spirometry (at least
 252 two 'acceptable' blows with no restriction on the range or coefficient of variation of these
 253 blows) 2,070 individuals met the criteria for inclusion. There were minimal changes to the
 254 effect sizes in the multivariable linear regression, and the 95% confidence intervals were
 255 narrower on account of the larger sample size (Supplementary Information S2). There were
 256 no changes to the direction or statistical significance of the results.

257 **Discussion**

258

259 The key finding of our study is that in a large cohort of individuals without prior diagnosis of
260 cardiorespiratory disease, lower lung function is associated with smaller left and right
261 ventricular end-systolic, end-diastolic, and stroke volumes; and with lower left ventricular
262 mass. These relationships are independent of other variables known to affect cardiac
263 structure. There was no association with ejection fraction.

264

265 The results of our study confirm and expand on previous work. The Multi Ethnic Study of
266 Atherosclerosis (MESA) lung substudy has previously identified relationships between
267 emphysema severity, quantified by thoracic computed tomography, and right and left
268 ventricular volumes and mass[9,10,18], although the consistency of the relationships varied
269 between analyses, and many of the patients had diagnoses of cardiovascular and respiratory
270 disease. In the same cohort, reduced FEV₁ to FVC ratio was associated with LV end-diastolic
271 volume and LV stroke volume[10], and with RV mass[9] although associations with FEV₁ and
272 FVC *per se* were not studied. Using echocardiography, Watz and colleagues[19] showed that
273 LV end-diastolic diameter and RV diameter are associated with FEV₁. Our study extends
274 these previous findings to a cohort without diagnosed heart or lung disease, and
275 demonstrates consistent relationships between spirometry and multiple measures of left
276 and right ventricular structure and function. The effect sizes seen in this study (2.34ml to
277 5.84ml per standard deviation change in FEV₁ or FVC) are comparable to those seen in
278 MESA[10] and in echocardiographic studies[19]. Furthermore, they are comparable in size

279 to the effects of systolic and diastolic blood pressure, and diabetes, all widely accepted
280 drivers of ventricular remodelling[20].

281

282 Age is a significant risk factor for cardiovascular morbidity and mortality[21,22], and is
283 associated with the development of ventricular fibrosis, remodelling, and diastolic
284 dysfunction[23]. Previous investigations have explored the relationship between age and
285 ventricular structure and function. Analysis of a subset of the UK Biobank CMR study, free
286 from all reported comorbid disease[13] showed a statistically significant negative
287 correlation between age and LV and RV end-diastolic, end-systolic, and stroke volumes; and
288 LV mass. Similar relationships were found using the MESA dataset[24,25], and in the current
289 study population.

290

291 In the current study, the variation in ventricular volumes and mass seen with lower FEV₁ and
292 FVC is comparable to that seen with ageing. Notably, the changes in CMR-derived
293 parameters per standard deviation of FEV₁ and FVC are approximately the same as those
294 seen with one decade of ageing. This suggests lower lung function is associated with a
295 'premature ageing' effect on the ventricle. This provides potential insight into the
296 mechanisms responsible for adverse cardiovascular outcomes in those with deranged lung
297 function, and highlights the potential importance of measuring lung function as a marker of
298 cardiovascular 'ageing' and risk.

299

300 Our analysis did not identify any relationship between ejection fraction and FEV₁, FVC, or
301 age, despite the significant influence of these factors on other measures of ventricular
302 function. Similar results were found in a MESA analysis of individuals with emphysema[10].

303 Our results add to the evidence that ejection fraction alone is an insensitive marker of
304 cardiac function and remodelling, particularly as it relates to respiratory function.

305

306 This study has several limitations. The design of UK Biobank renders it liable to selection
307 bias, and it is likely that the population recruited to the study is not completely
308 representative of the population as a whole. The self-reporting of co-morbidities and
309 lifestyle factors such as smoking is liable to ascertainment bias. The relatively low
310 prevalence of smoking observed in our study population may be explained, at least in part,
311 by these two factors.

312

313 Many participants were excluded from the analysis as their spirometry did not meet
314 conventional criteria for reproducibility and validity. It is possible that the variability in
315 spirometry arose from its acquisition in the non-specialist UK Biobank assessment centre,
316 rather than in a dedicated pulmonary function laboratory. Furthermore, the study protocol
317 limited participants to producing three blows, rather than repeating the measurement until
318 valid and reproducible results were achieved, as is commonly done in clinical practice.

319 Nonetheless, even after individuals with unacceptable variation had been excluded the full
320 range of FEV₁ and FVC were represented, and thus the ability to examine relationships
321 between these parameters and cardiac structure was preserved. Furthermore, the
322 sensitivity analysis revealed that exclusion of these individuals did not materially affect the
323 results, and suggests that no significant selection bias was introduced by the exclusion of
324 individuals with unacceptable spirometry. The inclusion only of individuals with
325 reproducible, high quality spirometry increases the confidence in the relationships identified
326 by this study.

327

328 This study raises a number of questions worthy of further analysis, including the long term
329 cardiovascular outcomes of patients with subclinical changes in lung function, the changes
330 in cardiovascular phenotype over time in patients with deranged spirometry, and evaluation
331 of ventricular fibrosis in those with impaired lung function through T1 mapping. These will
332 be amenable to investigation as longitudinal follow-up and parametric mapping data
333 become available from UK Biobank.

334 **Conclusions**

335

336 In a large cohort of patients without known cardiorespiratory disease, lower FEV₁ and FVC
337 are associated with smaller left and right ventricular volumes, and lower left ventricular
338 mass. The changes in ventricular structure per standard deviation fall in FVC and FEV₁ are
339 similar to those seen with a one decade increase in age, and may shed light on the
340 mechanisms underlying increased cardiovascular risk in those with subclinical changes in
341 lung function, as well as the importance of lung function as a risk factor for cardiovascular
342 disease.

343 **Acknowledgements**

344

345 This study was conducted using the UK Biobank resource under access application 2964.

346 **References**

347

- 348 1. European Respiratory Society. The burden of lung disease. In: Gibson J,
349 Loddenkemper R, Sibille Y, Lundback B, editors. European Lung White Book. European
350 Respiratory Society; 2017. pp. 1–14. Available: <http://erswhitebook.org>
- 351 2. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a
352 modifiable risk factor for cardiovascular disease? *Heart*. BMJ Publishing Group Ltd
353 and British Cardiovascular Society; 2012;98: 1055–1062. doi:10.1136/heartjnl-2012-
354 301759
- 355 3. Curkendall SM, Lanes S, de Luise C, Stang MR, Jones JK, She D, et al. Chronic
356 obstructive pulmonary disease severity and cardiovascular outcomes. *Eur J Epidemiol*.
357 Kluwer Academic Publishers; 2006;21: 803–813. doi:10.1007/s10654-006-9066-1
- 358 4. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W, Trevisan M. Pulmonary function is a
359 long-term predictor of mortality in the general population: 29-year follow-up of the
360 Buffalo Health Study. *Chest*. 2000;118: 656–664.
- 361 5. Sin DD, Wu L, Man SFP. The relationship between reduced lung function and
362 cardiovascular mortality: a population-based study and a systematic review of the
363 literature. *Chest*. 2005;127: 1952–1959. doi:10.1378/chest.127.6.1952
- 364 6. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung
365 function and mortality risk in men and women: findings from the Renfrew and Paisley
366 prospective population study. *BMJ*. BMJ Group; 1996;313: 711–5– discussion 715–6.

- 367 7. Martinez CH, Mannino DM, Jaimes FA, Curtis JL, Han MK, Hansel NN, et al.
368 Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and
369 Long-term Mortality. *Ann Am Thorac Soc. American Thoracic Society*; 2015;12: 1788–
370 1795. doi:10.1513/AnnalsATS.201506-388OC
- 371 8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.
372 Standardisation of spirometry. *The European respiratory journal. European*
373 *Respiratory Society*; 2005. pp. 319–338. doi:10.1183/09031936.05.00034805
- 374 9. Grau M, Barr RG, Lima JA, Hoffman EA, Bluemke DA, Carr JJ, et al. Percent
375 emphysema and right ventricular structure and function: the Multi-Ethnic Study of
376 Atherosclerosis-Lung and Multi-Ethnic Study of Atherosclerosis-Right Ventricle
377 Studies. *Chest*. 2013;144: 136–144. doi:10.1378/chest.12-1779
- 378 10. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent
379 emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med*.
380 2010;362: 217–227. doi:10.1056/NEJMoa0808836
- 381 11. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
382 access resource for identifying the causes of a wide range of complex diseases of
383 middle and old age. *PLoS Med*. 2015;12: e1001779.
384 doi:10.1371/journal.pmed.1001779
- 385 12. Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, et al.
386 UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson*.
387 *BioMed Central*; 2016;18: 8. doi:10.1186/s12968-016-0227-4

- 388 13. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, et al. Reference
389 ranges for cardiac structure and function using cardiovascular magnetic resonance
390 (CMR) in Caucasians from the UK Biobank population cohort. *J Cardiovasc Magn
391 Reson. BioMed Central*; 2017;19: 417. doi:10.1186/s12968-017-0327-9
- 392 14. UK Biobank. UK Biobank - Breath Spirometry [Internet]. 1st ed. 2011. Available:
393 www.ukbiobank.ac.uk
- 394 15. Tu Y-K, Clerehugh V, Gilthorpe MS. Ratio variables in regression analysis can give rise
395 to spurious results: illustration from two studies in periodontology. *Journal of
396 Dentistry*. 2004;32: 143–151. doi:10.1016/j.jdent.2003.09.004
- 397 16. Kronmal RA. Spurious Correlation and the Fallacy of the Ratio Standard Revisited.
398 *Journal of the Royal Statistical Society Series A (Statistics in Society)*. 1993;156: 379.
399 doi:10.2307/2983064
- 400 17. R Core Team. R [Internet]. Vienna, Austria. Available: www.r-project.org
- 401 18. Kawut SM, Poor HD, Parikh MA, Hueper K, Smith BM, Bluemke DA, et al. Cor
402 pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the
403 MESA COPD study. *J Am Coll Cardiol*. 2014;64: 2000–2009.
404 doi:10.1016/j.jacc.2014.07.991
- 405 19. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, et al. Decreasing
406 cardiac chamber sizes and associated heart dysfunction in COPD: role of
407 hyperinflation. *Chest*. 2010;138: 32–38. doi:10.1378/chest.09-2810

- 408 20. Heckbert SR, Post W, Pearson GDN, Arnett DK, Gomes AS, Jerosch-Herold M, et al.
409 Traditional Cardiovascular Risk Factors in Relation to Left Ventricular Mass, Volume,
410 and Systolic Function by Cardiac Magnetic Resonance Imaging. *J Am Coll Cardiol*.
411 2006;48: 2285–2292. doi:10.1016/j.jacc.2006.03.072
- 412 21. Dhingra R, Vasan RS. Age as a risk factor. *Med Clin North Am*. 2012;96: 87–91.
413 doi:10.1016/j.mcna.2011.11.003
- 414 22. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors,
415 and coronary heart disease: a prospective follow-up study of 14 786 middle-aged
416 men and women in Finland. *Circulation*. 1999;99: 1165–1172.
- 417 23. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ.
418 Burden of systolic and diastolic ventricular dysfunction in the community:
419 appreciating the scope of the heart failure epidemic. *JAMA*. 2003;289: 194–202.
- 420 24. Cheng S, Fernandes VRS, Bluemke DA, McClelland RL, Kronmal RA, Lima JAC. Age-
421 related left ventricular remodeling and associated risk for cardiovascular outcomes:
422 the Multi-Ethnic Study of Atherosclerosis. *Circ Cardiovasc Imaging*. American Heart
423 Association, Inc; 2009;2: 191–198. doi:10.1161/CIRCIMAGING.108.819938
- 424 25. Zemrak F, Ahlman MA, Captur G, Mohiddin SA, Kawel-Boehm N, Prince MR, et al. The
425 relationship of left ventricular trabeculation to ventricular function and structure over
426 a 9.5-year follow-up: the MESA study. *J Am Coll Cardiol*. 2014;64: 1971–1980.
427 doi:10.1016/j.jacc.2014.08.035
- 428

429 **Supplementary Information**

430

431 **S1 Supplementary Information**

432 Definitions of existing cardiorespiratory disease

433

434 **S2 Supplementary Information**

435 Sensitivity analysis exploring the impact of a less restrictive definition of valid and
436 reproducible spirometry that included all participants with at least two 'acceptable' blows
437 (as determined by the spirometer) without limitation on the coefficient of variation or
438 difference between the best and second best blow.

439

440 **S3 Supplementary Figure**

441 Univariable associations between CMR-derived parameters and FEV₁
442 Each panel shows the association between one CMR-derived parameter and FEV₁ prior to
443 the standardisation of the lung function. R² is the Pearson correlation coefficient between
444 the CMR-derived parameter and FEV₁ calculated on a complete pairs basis.

445

446 **S4 Supplementary Figure**

447 Univariable associations between CMR-derived parameters and FVC
448 Each panel shows the association between one CMR-derived parameter and FVC prior to
449 standardisation of the lung function. R² is the Pearson correlation coefficient between the
450 CMR-derived parameter and FVC calculated on a complete pairs basis.